← Back to Search

Steroid Synthesis Inhibitor

DST-2970 (Abiraterone) for Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by DisperSol Technologies, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is a Phase I study to test the safety and effectiveness of a new drug, DST-2970, in prostate cancer patients who have developed resistance to abiraterone acetate, a standard hormone therapy. The study will include a dose escalation phase followed by a dose expansion phase.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Body Weight Changes
Change in Tumor Size
Duration of response (DoR)
+3 more
Other study objectives
Exploration of potential biomarkers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prostate CancerExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abiraterone Acetate
2015
Completed Phase 4
~1880

Find a Location

Who is running the clinical trial?

DisperSol Technologies, LLCLead Sponsor
1 Previous Clinical Trials
25 Total Patients Enrolled
Translational Drug DevelopmentOTHER
18 Previous Clinical Trials
978 Total Patients Enrolled
1 Trials studying Prostate Cancer
23 Patients Enrolled for Prostate Cancer
~5 spots leftby Nov 2025